Press Releases Ypsomed Group

Burgdorf – Ypsomed (SIX: YPSN) has developed a new autoinjector platform for liquid medications with volumes ranging from 1.5 to 5.5 ml. The YpsoMate 5.5 is the latest addition to the growing YpsoMate family of devices and is based on the established technology of the YpsoMate 2.25 Pro. YpsoMate 5.5 enables the self-administration of larger volume medications for treating cancer, rare and autoimmune diseases.

YpsoMate 5.5

With the increasing use of therapeutic proteins administered subcutaneously, the use of autoinjectors has steadily increased in recent years and continues to rise. Self-medication makes daily life easier for many people with chronic diseases and reduces the burden on the healthcare system. Thanks to easy-to-use self-injection systems such as the YpsoMate autoinjector with pre-filled syringe, patients can treat themselves at home instead of visiting a medical facility to do so. Larger dosing volumes can reduce the number of injections required, further reducing the treatment burden for patients and caregivers.

Making selfcare simpler and easier

YpsoMate 5.5 represents the newest member of the YpsoMate autoinjector family and expands the application range of current autoinjectors by enabling the administration of larger volumes in the range of 2.0 to 5.5 ml from a pre-filled syringe. We are setting a new standard for self-management of chronic diseases,

says Ulrike Bauer, Chief Business Officer Delivery Systems at Ypsomed.

Product design promotes easy and safe handling

Simplicity and safe handling are crucial. The YpsoMate 5.5 features the two-step handling already well proven in YpsoMate models: Removing the cap and pushing on the skin. The injection process is triggered automatically. During product design, special focus was placed on providing optimal support for larger volumes and a longer injection duration. The YpsoMate 5.5 is equipped with a handgrip that allows comfor-table handling and a stable hand position during injection. A continuous visual and audible signal gives the user good control over the entire injection process.

Ready-to-use syringe in collaboration with Schott Pharma

The YpsoMate 5.5 features an integrated, pre-filled syringe developed in collaboration with Schott, a leading manufacturer of storage and delivery systems for medicines. It leverages existing standards and components to optimize processes for pharmaceutical customers and shorten time-to-market, reduce development risks, ensure suitability for sensitive drugs and facilitate compatibility with existing filling equipment. The result of the joint development is the syriQ BioPure 5.5 mL, a large-volume, prefillable syringe with integrated needle.

Thomas Kutt
Head of Investor Relations
Ypsomed Holding AG